Does Positron Emission Tomography Change Management in Primary Rectal Cancer? A Prospective Assessment

Diseases of the Colon and Rectum

Volumn 47, Issue 4, 2004, Pages 451-458

  Heriot, Alexander G ^a   Hicks, Rodney J ^b   Drummond, Elizabeth G P ^b   Keck, Jamie ^a   Mackay, John ^a,b,c   Chen, Frank ^c   Kalff, Victor ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c BOX HILL HOSPITAL   (Australia)

Author keywords

Positron emission tomography; Preoperative staging; Rectal carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; DEVICE; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; RECTUM CANCER; ULTRASOUND SCANNER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT CARE PLANNING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1842422119     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10350-003-0089-3     Document Type: Article

References (38)

1. Jemal A, Thomas A, Murrey T, Thun M. Cancer Statistics. CA Cancer J Clin 2002;52:23-47
2. Jensen O, Esteve J, Moller H, Renard H. Cancer in the European community and its member states. Eur J Cancer 1990;26:1167-256
3. Myers M, Ries L. Cancer patient survival rates: SEER program results for 10 years of follow-up. CA Cancer J Clin 1989;39:21-32
4. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001;358:1291-304
5. Gibbs P, Chao MW, Tjandra JJ. Optimizing the outcome for patients with rectal cancer. Dis Colon Rectum 2003;46:389-402
6. Saltz L, Minsky B. Adjuvant therapy of cancers of the colon and rectum. Surg Clin N Am 2002;82:1035-58
7. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59-71
8. Heriot A, Grundy A, Kumar D. Preoperative staging of rectal carcinoma. Br J Surg 1999;86:17-28
9. Moss A. Imaging of colorectal cancer. Radiology 1989;170:308-10
10. Beynon J, Mortensen NJ, Rigby HS. Rectal endosonography, a new technique for the preoperative staging of rectal carcinoma. Eur J Surg Oncol 1988;14:297-309
11. Brown G, Richards C, Dallimore N, et al. Rectal carcinoma: thin section MR imaging for staging in 28 patients. Radiology 1999;211:215-22
12. Leen E, Angerson W, Wotherspoon H, Moule B, Cook T, McArdle C. Detection of colorectal liver metastases: comparison of laparotomy, CT, US, and Doppler perfusion index and evaluation of postoperative follow-up results. Radiology 1995;195:113-6
13. Hoh C, Schiepers C, Seltzer M, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997;27:94-106
14. Falk PM, Gupta NC, Thorson AG, et al. Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum 1994;37:153-6
15. Abdel-Nabi H, Doerr R, Lamonica D, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206:755-60
16. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-20
17. Mukai M, Sadahiro S, Yasuda S, et al. Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep 2000;7:85-7
18. Meta J, Seltzer M, Schiepers C, et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med 2001;42:586-90
19. Kalff V, Hicks R, Ware R, Hogg A, Binns D, McKenzie A. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002;43:492-9
20. Sobin L, Wittekind C. UICC International Union Against Cancer: TNM classification of malignant tumours. 5th ed. New York: John Wiley and Sons, 1997:67-8.
21. Crippa F, Gavazzi C, Bozzetti F, et al. The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas. Tumori 1997;83:748-52
22. Miraldi F, Vesselle H, Faulhaber P, Adler L, Leisure G. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 1998;23:3-7
23. Karp JS, Muehllehner G, Mankoff DA, et al. Continuous-slice PENN-PET: a positron tomograph with volume imaging capacity. J Nucl Med 1990;31:617-27
24. Fulham M, Meikle S, Hooper P, Silver K. Lesion detection in whole body FDG PET using simultaneous emission transmission acquisition and OSEM reconstruction (SET-OSEM) versus emission only (OE) and FBP reconstruction: an ROC study. J Nucl Med 1997;37:78P
25. Benard F, Smith R, Hustinx P, Karp K, Alavi A. Clinical evaluation of processing techniques for attenuation correction with 137-Cs in whole-body PET imaging. J Nucl Med 1999;40:1257-63
26. Arulampalam T, Costa D, Loizidou M, Visvikis D, Ell P, Taylor I. Positron emission tomography and colorectal cancer. Br J Surg 2001;88:176-89
27. Boykin KN, Zibari GB, Lilien DB, McMillan R, Aultman D, McDonald J. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver. Am Surg 1999;65:1183-5
28. Fong Y, Saldinger P, Akhurst T, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999;178:282-7
29. Lai D, Fulham M, Stephens M, et al. The role of wholebody positron emission tomography with F-18 fluorodeoxyglucose in recurrent colorectal cancer metastases to the liver. Arch Surg 1996;131:703-7
30. Valk PE, Abella-Columna E, Hasemann M, et al. Whole body PET imaging with 18-F fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503-11
31. Imdahl A, Reinhardt M, Nitzsche E, et al. Impact of 18F-FDG positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000;385:129-34
32. Delbeke D, Vitola J, Sandler M, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21-6
33. Beyer T, Townsend D, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-79
34. Freeny P. Helical computed tomography of the liver: techniques, applications and pitfalls. Endoscopy 1997;29:515-23
35. Vitola J, Delbeke D, Sandler M, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21-6
36. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-2001
37. MacManus MP, Hicks RJ, Mathews J, et al. High rate of detection of unsuspected distant metastases by PET in apparant stage III non-small cell lung cancer: implications for radical radiotherapy. Int J Radiat Oncol Biol Phys 2001;50:287-93
38. Brennan M. PET scanning in malignancy: infant, adolescent, or mature citizen? Ann Surg 2001;233:320-1